AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Go back to AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma| AbbVie (NYSE: ABBV) | Delayed: 253.30 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $253.30 | 52 Week High | $68.12 | |||
| Open | $253.30 | 52 Week Low | $50.71 | |||
| Day High | $253.30 | P/E | 54.95 | |||
| Day Low | $253.30 | EPS | $4.61 | |||
| Volume | 113,865 | |||||
